An analogous approach could be feasible for treating the optic neuropathy associated with MTRFR deficiency; however, delivery directly to the eye would not treat the peripheral neuropathy and other symptoms of MTRFR deficiency. This evidence concerns the gene MTRFR and peripheral neuropathy.